Novo Nordisk and Fangzhou have signed a Memorandum of Understanding (MoU) to develop a comprehensive health management ecosystem for chronic diseases.
Focusing on diabetes and obesity, the partnership will leverage Novo Nordisk’s expertise and Fangzhou’s AI-driven healthcare solutions to enhance patient care.
Fangzhou will leverage its smart healthcare ecosystem and advanced technology to offer medication guidance, reminders, efficacy tracking, and health education services.
The initiative aims to transition from a ‘disease-centred’ to a ‘health-centred’ model, providing patients with high-quality, convenient healthcare services.
Novo Nordisk senior vice president and China region president Christine Zhou said: “With the combined strengths of both companies, this collaboration will closely integrate chronic disease prevention and digital innovation technology, jointly enhancing public awareness of diabetes and obesity.
“It will also support the aim that the concepts of early screening, early diagnosis, and early treatment are effectively implemented within smart healthcare environments.”
Both companies are committed to exploring further innovative collaborations in the digital transformation of the medical industry.
Fangzhou, an online chronic disease management platform, serves 49.2 million registered users and 223,000 physicians in China. It offers tailored medical care and precision medicine solutions.
Fangzhou founder, chairman, and CEO Xie Fangmin said: “We are partnering with Novo Nordisk, a leading global healthcare company, to explore AI technology and address the pain points of traditional health management.
“Together, we aim to deliver innovative digital solutions for managing blood sugar and weight on a global scale.”
Earlier this year, Novo Nordisk expanded its agreement with Valo Health to develop treatments for obesity, type 2 diabetes, and cardiovascular disease.
The expanded collaboration leverages Valo’s Opal Computational Platform and Novo Nordisk’s expertise in cardiometabolic diseases.
Under the terms of the agreement, Valo may receive up to $4.6bn in milestone payments, R&D funding, and potential royalties.
